Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 24Myelodysplastic Syndromes 5Myeloproliferative Disorders 3Leukemia, Biphenotypic, Acute 3Leukemia, Myeloid 2Leukemia 2Blast Crisis 2Sarcoma, Myeloid 1Neoplasms by Histologic Type 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Carcinoma, Hepatocellular 1Anemia, Refractory, with Excess of Blasts 1

Interventions

ruxolitinib 9fludarabine phosphate 8fludarabine 8Whole-Body Irradiation 8Specimen Handling 7Cytarabine 7Cyclophosphamide 7Mycophenolic Acid 6Tacrolimus 5Injections 5Busulfan 5Biopsy 5Azacitidine 5Stem Cell Transplantation 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Granulocyte Colony-Stimulating Factor 4CPX-351 4venetoclax 3luspatercept 3decitabine and cedazuridine drug combination 3Liposomes 3Idarubicin 3Daunorubicin 3Cyclosporine 3Blood Specimen Collection 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3selinexor 2nilotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Idarubicin × 90 days × Clear all
NCT04250051 2026-06-01

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Northwestern University

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT06034470 2026-05-07

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡